A pharmaceutical composition comprising a compound of the formula IIB: ** Formula ** or one of its pharmaceutically acceptable salts, solvates, stereoisomers and / or esters where: R10a and R10b are each, independently, H or -C1-4 I rent； R12 is H or -CH3； R13 is - (CH2) 0-3CR17R18NR20R21, - (CH2) 0-3CR17R18NR17C (O) NR20R21, - (CH2) 1-3C (O) R22, - (CH2) 1-3S (O) 2R22 or - (CH2) 1-3-R23； R14 and R15 are each, independently, H, -C1-4 alkyl or arylalkyl； R17 and R18 are each independently, H or -C1-3 alkyl； R19 is H, -C1-4 alkyl or arylalkyl； R20 and R21 are each independently H, -C1-3 alkyl, -C (O) R17 or -S (O) 2R17； or R20 and R21, taken in conjunction with the nitrogen atom to which they adhere, form a substituted or unsubstituted 5-6 membered heterocyclyl ring containing 1-2 selected heteroatoms a group consisting of N and O； R22 is H, -C1-3alkyl, -OR19 or -NR20R21； and R23 is an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from a group consisting of N and O； wherein said substituted or unsubstituted 5-6 membered heterocyclyl ring consisting of R20 and R21 and said substituted or unsubstituted 5-6 membered 5-6 heterocyclyl ring of R23 are substituted or not independently substituted with a C1-2 alkyl, a pharmaceutically acceptable carrier or excipient and darunavir or a pharmaceutically acceptable salt, solvate and / or ester thereof.Una composición farmacéutica que comprende a un compuesto de la fórmula IIB:**Fórmula** o una de sus sales, solvatos, estereoisómeros y/o ésteres farmacéuticamente aceptables donde: R10a y R10b son cada uno, independientemente, H o -C1-4 alquilo； R12 es H o -CH3； R13 es -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O) NR20R21, -(CH2)1-3C(O)R22, -(CH2)1-3S(O)2R22 o -(CH2)1-3-R23； R14 y R15 son cada uno, independientemente, H, -C1-4 alquilo o arilalquilo； R17 y R18 son cada uno independientemente, H o -C1-3 alquilo； R19 es H, -C1-4 alquilo o arilalquilo； R20 y R21 son cada uno, indep
